FDA approves test for molecular residual disease monitoring in patients with solid tumors

Abstract

This news section offers Cancer readers timely information on events, public policy analysis, and topical issues. In this issue, the FDA approves a test that enables the identification of patients who are positive for ctDNA and can benefit from adjuvant atezolizumab after cystectomy. In addition, the HERMES trial supports a shortened stereotactic body radiation therapy schedule without added toxicity for patients with prostate cancer, and the FDA grants accelerated approval to BCL‐2 inhibitor sonrotoclax for mantle cell lymphoma.